Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Summary not available.
Seer (Nasdaq: SEER) announced its Board unanimously rejected a revised unsolicited proposal from the Radoff-JEC Group received April 24, 2026, offering $2.35 per share in cash plus a contingent value right. The Board concluded the proposal materially undervalues Seer versus cash, investments and platform value.
The Board highlighted Seer’s Proteograph product suite, selection for Singapore’s SGK100 study, more than 80 peer‑reviewed publications, and 240 patents and applications (82 issued), and said stockholders need take no action at this time.
Summary not available.
Seer (Nasdaq: SEER) confirmed receipt of a non-binding, unsolicited proposal from the Radoff-JEC Group to acquire all Class A shares for $2.25 per share in cash plus a contingent value right.
The group also nominated three director candidates for Seer’s 2026 Annual Meeting. The Board, with financial and legal advisors, will review the Proposal and nominations; no stockholder action is required at this time.
Summary not available.
Seer (Nasdaq: SEER) will provide its Proteograph product suite to deeply profile the plasma proteome in 10,000 PRECISE-SG100K participant samples, integrated with Thermo Fisher Olink Reveal and Orbitrap Astral data.
The collaboration aims to add deep, unbiased proteomics to a ~100,000-person, multi-ancestry Singapore cohort to support biomarker discovery, drug target biology, and population-level risk models.
Seer (Nasdaq: SEER) said the U.S. Patent and Trademark Office Patent Trial and Appeal Board issued a Final Written Decision on March 23, 2026 upholding 23 claims of U.S. Patent No. 11,435,360, which protect its Proteograph nanoparticle protein enrichment methods.
The ’360 patent is owned by Brigham and Women’s Hospital and exclusively licensed to Seer; the decision affirms key claim coverage of Proteograph’s nano- and microparticle protein-corona technology.
Seer noted the platform is supported by an IP portfolio of more than 240 issued and pending patents, including 80 issued patents.
Summary not available.
Seer (Nasdaq: SEER) adopted a limited-duration tax benefit preservation plan to protect approximately $262 million of net operating loss carryforwards as of December 31, 2025. The plan seeks to limit ownership accumulation above 4.9% of Class A stock without Board approval.
The Board declared a dividend of one transferable right per outstanding Class A share, with a record date of March 9, 2026. The NOL Plan expires February 25, 2029, or earlier on February 25, 2027 if shareholders do not ratify it at Seer’s 2026 annual meeting.
Seer (Nasdaq: SEER) reported fourth-quarter and full-year 2025 results, with $4.2M revenue in Q4 and $16.6M for full year 2025. Installed base grew to 82 instruments (67% YoY) and year-end cash, cash equivalents and investments were approximately $240.6M.
Gross margin was ~51% for 2025, operating expenses fell to $86.5M, and net loss narrowed to $73.6M. Seer expects 2026 revenue of $16M–$18M (midpoint ~3% growth).